Panacea Biotec Limited

Panacea Biotec Limited

Panacea Biotec Limited has received a Show Cause Notice from the Assistant Commissioner, GST, Delhi, alleging a tax liability of ₹4.06 Crore on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The company's wholly owned subsidiary, Panacea Biotec Pharma Limited, is in the process of preparing a response against the notice.

Panacea Biotec Limited

Panacea Biotec Limited has informed the Exchange about the pendency of litigation or dispute(s) or the outcome impacting the Company. The Company has received four awards from the Presiding Officer of Industrial Tribunal, S.A.S. Nagar, Mohali, and has filed an appeal against the remaining fourth award. The Hon'ble High Court has passed an interim order stating that no coercive steps be taken against the Company.

Panacea Biotec Limited

Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during June 2026'. The company has confirmed that no shares were dematerialized during the month of June 2026, with a total of 6,11,05,526 shares dematerialized as on June 30, 2026.

Panacea Biotec Limited

Panacea Biotec Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended June 30, 2026.

Panacea Biotec Limited

Panacea Biotec Limited has informed the Exchange about the pendency of litigation or dispute(s) or the outcome impacting the Company. The Company has received four Awards from the Presiding Officer of Industrial Tribunal, S.A.S. Nagar, Mohali, and has filed appeals against three of them in the Hon'ble High Court of Punjab and Haryana, Chandigarh.

Panacea Biotec Limited

Panacea Biotec Limited has informed the Exchange regarding the closure of the trading window for its designated persons due to the upcoming unaudited financial results for the quarter ending June 30, 2026.